OPTIMIZERX CORP (OPRX)
US68401U2042 - Common Stock
OPRX gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 37 industry peers in the Health Care Technology industry. OPRX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. OPRX is growing strongly while it is still valued neutral. This is a good combination!
1. Profitability
1.1 Basic Checks
In the past year OPRX was profitable.
In the past year OPRX has reported a negative cash flow from operations.
In the past 5 years OPRX reported 4 times negative net income.
In multiple years OPRX reported negative operating cash flow during the last 5 years.
1.2 Ratios
With a decent Return On Assets value of -10.36%, OPRX is doing good in the industry, outperforming 66.67% of the companies in the same industry.
Looking at the Return On Equity, with a value of -14.81%, OPRX is in the better half of the industry, outperforming 69.44% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -10.36% | ||
| ROE | -14.81% | ||
| ROIC | N/A |
ROA(3y)-5.93%
ROA(5y)-5.4%
ROE(3y)-7.55%
ROE(5y)-6.82%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Gross Margin, with a value of 61.96%, OPRX is in line with its industry, outperforming 47.22% of the companies in the same industry.
OPRX's Gross Margin has been stable in the last couple of years.
OPRX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 61.96% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.52%
GM growth 5Y0.83%
2. Health
2.1 Basic Checks
OPRX does not have a ROIC to compare to the WACC, probably because it is not profitable.
OPRX has more shares outstanding than it did 1 year ago.
The number of shares outstanding for OPRX has been increased compared to 5 years ago.
OPRX has a worse debt/assets ratio than last year.
2.2 Solvency
OPRX has an Altman-Z score of 0.67. This is a bad value and indicates that OPRX is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of OPRX (0.67) is comparable to the rest of the industry.
A Debt/Equity ratio of 0.27 indicates that OPRX is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.27, OPRX perfoms like the industry average, outperforming 50.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.27 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 0.67 |
ROIC/WACCN/A
WACC8.34%
2.3 Liquidity
OPRX has a Current Ratio of 3.07. This indicates that OPRX is financially healthy and has no problem in meeting its short term obligations.
With a decent Current ratio value of 3.07, OPRX is doing good in the industry, outperforming 72.22% of the companies in the same industry.
OPRX has a Quick Ratio of 3.07. This indicates that OPRX is financially healthy and has no problem in meeting its short term obligations.
With a decent Quick ratio value of 3.07, OPRX is doing good in the industry, outperforming 72.22% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.07 | ||
| Quick Ratio | 3.07 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 20.83% over the past year.
OPRX shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 9.58% yearly.
Looking at the last year, OPRX shows a quite strong growth in Revenue. The Revenue has grown by 14.53% in the last year.
OPRX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 27.52% yearly.
EPS 1Y (TTM)20.83%
EPS 3Y9.58%
EPS 5YN/A
EPS Q2Q%33.33%
Revenue 1Y (TTM)14.53%
Revenue growth 3Y18.2%
Revenue growth 5Y27.52%
Sales Q2Q%30.49%
3.2 Future
OPRX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 51.96% yearly.
Based on estimates for the next years, OPRX will show a very strong growth in Revenue. The Revenue will grow by 21.36% on average per year.
EPS Next Y44.57%
EPS Next 2Y42.09%
EPS Next 3Y51.96%
EPS Next 5YN/A
Revenue Next Year42.85%
Revenue Next 2Y27.01%
Revenue Next 3Y21.36%
Revenue Next 5YN/A
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
OPRX is valuated correctly with a Price/Earnings ratio of 14.40.
94.44% of the companies in the same industry are more expensive than OPRX, based on the Price/Earnings ratio.
OPRX's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 28.81.
OPRX is valuated reasonably with a Price/Forward Earnings ratio of 8.27.
Based on the Price/Forward Earnings ratio, OPRX is valued cheaply inside the industry as 97.22% of the companies are valued more expensively.
OPRX's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 23.56.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 14.4 | ||
| Fwd PE | 8.27 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
OPRX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
OPRX's earnings are expected to grow with 51.96% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.32
PEG (5Y)N/A
EPS Next 2Y42.09%
EPS Next 3Y51.96%
5. Dividend
5.1 Amount
No dividends for OPRX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
OPTIMIZERX CORP
NASDAQ:OPRX (11/15/2024, 10:00:59 AM)
4.175
+0.12 (+2.83%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap76.49M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 14.4 | ||
| Fwd PE | 8.27 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)0.32
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -10.36% | ||
| ROE | -14.81% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 61.96% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.48
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.27 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 3.07 | ||
| Quick Ratio | 3.07 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)20.83%
EPS 3Y9.58%
EPS 5Y
EPS Q2Q%
EPS Next Y44.57%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)14.53%
Revenue growth 3Y18.2%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y